January 28, 2021 |
|
VIA EDGAR AND OVERNIGHT DELIVERY
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-6010
| Attention: Tracie | Mariner |
Mary Mast
Ada D. Sarmento
Mary Beth Breslin
| Re: | Sana Biotechnology, Inc. |
Registration Statement on Form S-1 |
Filed January 13, 2021 |
File No. 333-252061 |
Ladies and Gentlemen:
On behalf of our client, Sana Biotechnology, Inc. (the “Company”), we are hereby submitting to the Securities and Exchange Commission (the “Commission”) Amendment No. 1 (“Amendment No. 1”) to the Company’s Registration Statement on Form S-1 (the “Registration Statement”). The Company previously filed a Registration Statement on Form S-1 on January 13, 2021 (the “First Public Filing”) and submitted draft Registration Statements on Form S-1 on a confidential basis, pursuant to Title I, Section 106 under the Jumpstart Our Business Startups Act, on November 10, 2020 and on December 18, 2020. The Registration Statement filed concurrently with this letter has been revised to reflect the Company’s responses to the comment letter to the First Public Filing dated January 23, 2021 from the staff of the Commission (the “Staff”) as well as other revisions and updates to its disclosure. For your convenience, we are providing by overnight delivery a courtesy package that includes copies of the Registration Statement, including copies which have been marked to show changes from the First Public Filing, as well as copy of this letter.
January 28, 2021
Page 2
For ease of review, we have set forth below the numbered comment of your letter in bold type followed by the Company’s response thereto.
January 23, 2021 Comment Letter
Business
Preclinical Development of Hypoimmune Cells, page 156
| 1. | Please remove the reference to “promising” early results from the NHP hypoimmune iPSC transplantation experiments in this section. |
Response: In response to the Staff’s comment, the Company has revised page 156 of the Registration Statement to remove the reference to “promising” in the identified location.
Financial statements for the interim period ended September 30, 2020
17. Subsequent Events, page F-58
| 2. | Please tell us why you have not disclosed any significant equity issuances such as the options granted since September 30, 2020. |
Response: In response to the Staff’s comment, the Company has revised page F-58 of the Registration Statement.
* * *
January 28, 2021
Page 3
We hope the foregoing answers are responsive to your comments. Please do not hesitate to contact me by telephone at (650) 463-3014 or by email to Brian.Cuneo@lw.com with any questions or comments regarding this correspondence.
Very truly yours,
Brian J. Cuneo
of LATHAM & WATKINS LLP
| cc: | Steven D. Harr, M.D., Sana Biotechnology, Inc. |
James J. MacDonald, Sana Biotechnology, Inc. |
B. Shayne Kennedy, Latham & Watkins LLP |
Charles S. Kim, Cooley LLP |
Kristin VanderPas, Cooley LLP |